Xcout Intel
Dignify Therapeutics, LLC competitors & alternatives
The 12 closest competitors and alternatives to Dignify Therapeutics, LLC among pharmaceuticals companies — ranked by similarity to what Dignify Therapeutics, LLC actually does, not by market-cap band.
Subscribe to see Dignify Therapeutics, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Dignify Therapeutics, LLC
Dignify Therapeutics is a biotechnology company located in Research Triangle Park, North Carolina. The company focuses on developing pharmaceutical solutions to bolster bowel and bladder control for patients.
Dignify Therapeutics, LLC at a glance
Dignify Therapeutics, LLC is a pharmaceuticals company headquartered in United States, founded in 2013. It has raised at least $1.6M across the 2 funding rounds on record. Its most recent funding round raised $800,000 in September 2026. Xcout tracks 17 named people at Dignify Therapeutics, LLC, including Anthony DiTonno (CEO).
Dignify Therapeutics, LLC leadership
- Anthony DiTonnoCEO
- Benny WardCEO
- Ed Burgard, Ph.D.President
- Jeff WelchChief Operating Officer
- Karl Thor, Ph.D.Chief Scientific Officer
- Dan Ricca, Ph.D.VP of Chemistry
11 more named people on record for Dignify Therapeutics, LLC, with roles, board committees and tenure — see the full roster →
Dignify Therapeutics, LLC funding rounds
At least $1.6M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $800,000 | — | |
| Grant | $800,000 | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Dignify Therapeutics, LLC competitors
Ranked by semantic similarity — how close each company is to Dignify Therapeutics, LLC by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Incyclix Bio is an oncology therapeutics company headquartered in Research Triangle Park, North Carolina. Founded by pioneers in CDK inhibitor discovery, research, and development, the company focuses on creating innovative cancer treatments.
Similar pharmaceuticals company
RDD Pharma Ltd. is a biopharmaceutical company focused on the discovery and development of therapeutic products for gastrointestinal and anorectal diseases. Headquartered in Israel with locations in Tel Aviv and Ofakim, the company specializes in targeted treatments.
Pharmaceutical Manufacturing
Emergo Therapeutics, Inc. is a biopharmaceutical holding company and startup headquartered in Durham, North Carolina, focused on drug pipelines and the production of inflammatory cytokines.
Similar pharmaceuticals company
LifeWell is a pharmaceutical company founded in Portugal in 2016 that researches, develops, and commercializes innovative therapeutic solutions in gynecology, obstetrics, fertility, and urology.
Similar pharmaceuticals company
Slate Medicines is a privately held biotechnology company advancing next-generation therapeutics for headache treatment, with headquarters located in Raleigh, North Carolina and Boston, Massachusetts.
Pharma
Dicot Pharma is a pharmaceutical company that develops new potency drugs targeting sexual dysfunctions in men. Its primary drug candidate, LIB-01, is designed to treat erectile dysfunction with a prolonged duration of action. The company serves patients and healthcare markets by focusing on next-generation treatments to improve quality of life.
Similar pharmaceuticals company
Ferring Pharmaceuticals is a specialty biopharmaceutical company that develops and delivers treatments in reproductive medicine, maternal health, gastroenterology, urology, and uro-oncology. The company focuses on helping people build families, supporting maternal and infant health, and providing therapeutic solutions for various medical conditions worldwide.
Similar pharmaceuticals company
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
Similar pharmaceuticals company
InDex Pharmaceuticals is a Swedish biotechnology company developing immunomodulatory therapies for inflammatory diseases. Its lead drug candidate, cobitolimod, has been investigated as a treatment for moderate-to-severe ulcerative colitis, serving patients with inflammatory bowel disease.
Similar pharmaceuticals company
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Similar pharmaceuticals company
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.
Medical - Pharmaceuticals
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Dignify Therapeutics, LLC and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Dignify Therapeutics, LLCand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →